1
|
Tortosa-Carreres J, Lloret-Sos C, Sahuquillo-Arce JM, Suárez-Urquiza P, Prat-Fornells J, Molina-Moreno JM, Alba-Redondo A, Martínez-Triguero ML, Aguado-Codina C, Laiz-Marro B, López-Hontangas JL. Evaluating the diagnostic performance of Liaison® chemiluminescence assay as screening tool for detection of acute Epstein-Barr infection: A comparative study. Diagn Microbiol Infect Dis 2024; 108:116167. [PMID: 38176302 DOI: 10.1016/j.diagmicrobio.2023.116167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 12/15/2023] [Accepted: 12/23/2023] [Indexed: 01/06/2024]
Abstract
The present investigation assessed the Liaison® diagnostic performance in detecting Epstein-Barr (EBV) IgM-VCA in a large patient cohort, considering age and symptomatology. VIDAS® were employed as a benchmark for acute EBV infection. The study also probed other coexisting conditions and potential cross-reactivity for error sources. A total of 1311 samples were analyzed, with notable associations found only among paediatric (kappa=0.75) and young adult (kappa=0.58) populations with compatible symptoms. ROC analysis revealed varying optimal cutoff values based on age and symptom categorizations. Logistic regression models identified age and patients from Oncology or Infectious Disease as significant factors for false positives. Potential interferences emerged with RF, ANCA, cytomegalovirus-IgM and VHS-IgM. Notably, Liaison® couldn´t distinguish EBV patients from Oncology, Haemathology or Internal Medicine. This study provides valuable insights, such as implementing ageand symptom-specific thresholds or reviewing test requests, for optimizing EBV serology in microbiology laboratories, leading to faster and more reliable responses.
Collapse
Affiliation(s)
- Jordi Tortosa-Carreres
- Laboratory Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Carmen Lloret-Sos
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Jose Miguel Sahuquillo-Arce
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Pedro Suárez-Urquiza
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Josep Prat-Fornells
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Jose Miguel Molina-Moreno
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Amparo Alba-Redondo
- Laboratory Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Maria Luisa Martínez-Triguero
- Laboratory Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Cristina Aguado-Codina
- Laboratory Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Begoña Laiz-Marro
- Laboratory Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| | - Jose Luis López-Hontangas
- Microbiology Department, Hospital Univeritari i Politècnic la Fe. Av Fernando Abril Martorell 106; 46026 València, Spain.
| |
Collapse
|
2
|
Kueht ML, Dongur LP, Mujtaba MA, Cusick MF. Antibody Therapeutics as Interfering Agents in Flow Cytometry Crossmatch for Organ Transplantation. J Pers Med 2023; 13:1005. [PMID: 37373995 DOI: 10.3390/jpm13061005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 05/31/2023] [Accepted: 06/05/2023] [Indexed: 06/29/2023] Open
Abstract
Donor-recipient matching is a highly individualized and complex component of solid organ transplantation. Flowcytometry crossmatching (FC-XM) is an integral step in the matching process that is used to detect pre-formed deleterious anti-donor immunoglobulin. Despite high sensitivity in detecting cell-bound immunoglobulin, FC-XM is not able to determine the source or function of immunoglobulins detected. Monoclonal antibody therapeutic agents used in a clinic can interfere with the interpretation of FC-XM. We combined data from the prospectively maintained Antibody Society database and Human Protein Atlas with a comprehensive literature review of PubMed to summarize known FC-XM-interfering antibody therapeutics and identify potential interferers. We identified eight unique FC-XM-interfering antibody therapeutics. Rituximab (anti-CD20) was the most-cited agent. Daratumuab (anti-CD38) was the newest reported agent. We identified 43 unreported antibody therapeutics that may interfere with FC-XM. As antibody therapeutic agents become more common, identifying and mitigating FC-XM interference will likely become an increased focus for transplant centers.
Collapse
Affiliation(s)
- Michael L Kueht
- Department of Surgery, Multiorgan Transplant and Hepatobiliary Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
| | - Laxmi Priya Dongur
- Department of Surgery, Multiorgan Transplant and Hepatobiliary Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
| | - Muhammad A Mujtaba
- Department of Medicine, Transplant Nephrology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
| | - Matthew F Cusick
- Department of Pathology, Division of Histocompatibility and Immunogenetics, University of Michigan Medicine, 2800 Plymouth Rd., Building 36, Ann Arbor, MI 48109, USA
| |
Collapse
|
3
|
A Novel Blocking Enzyme-Linked Immunosorbent Assay Based on a Biotinylated Nanobody for the Rapid and Sensitive Clinical Detection of Classical Swine Fever Virus Antibodies. Microbiol Spectr 2023; 11:e0299622. [PMID: 36688674 PMCID: PMC9927282 DOI: 10.1128/spectrum.02996-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Monoclonal and polyclonal antibodies are mostly used for the development of traditional enzyme-linked immunosorbent assays (ELISAs), but the use of certain conventional antibodies may be limited by their low yield, the difficulty of their isolation, and their high cost. Heavy-chain antibodies derived from camelids with naturally missing light chains can overcome these deficiencies and are an excellent alternative to conventional antibodies. In this study, a nanobody (Nb)-AviTag fusion protein was constructed, and the feasibility of its use as a high-sensitivity probe in a blocking ELISA (bELISA) for classical swine fever virus (CSFV) was investigated. The CSFV E2 recombinant protein expressed by the CHO expression system exhibited good reactogenicity and immunogenicity and induced the production of high CSFV antibody levels in rabbits. Three different clones of Nbs were successfully isolated using a phage display system in alpaca, and an Nb1-AviTag fusion protein was successfully expressed using an Escherichia coli expression system. The purified Nb1-AviTag fusion protein was then biotinylated in vitro to obtain Nb1-biotin. A novel bELISA was developed for the detection of CSFV antibodies in clinical serum using Nb1-biotin as a probe. The cutoff value of bELISA was 32.18%, the sensitivity of bELISA was higher than that of the bELISA kit with IDEXX antibody, and the coincidence rate was 94.7%. A rapid, low-cost, highly sensitive and highly specific CSFV E2 antibody-based bELISA method was successfully established and can be used for the serological evaluation of CSFV E2 subunit vaccines and the ELISA-based diagnosis of CSFV infection. IMPORTANCE Currently, the epidemic situation of classical swine fever (CSF) is sporadic, and cases of atypical swine fever are on the rise in China. Therefore, it is necessary to accurately eliminate suspected cases by using highly sensitive and specific diagnostic techniques. In our study, a rapid, low-cost, highly sensitivity, highly reliable and reproducible, and highly specific classical swine fever virus (CSFV) E2 antibody-based blocking ELISA method was successfully established by using the phage display system and the Nb1-AviTag fusion expression platform. It provides a new technique for serological evaluation of CSFV vaccines and ELISA-based diagnosis of CSFV infection.
Collapse
|
4
|
Ostrov BE. Reliability and reproducibility of antinuclear antibody testing in pediatric rheumatology practice. Front Med (Lausanne) 2023; 9:1071115. [PMID: 36714114 PMCID: PMC9875300 DOI: 10.3389/fmed.2022.1071115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2022] [Accepted: 12/13/2022] [Indexed: 01/11/2023] Open
Abstract
Antinuclear antibody (ANA) testing is common practice among health care practitioners when evaluating children and adolescents with non-specific symptoms including fatigue and aches and pains. When positive, ANA results often lead to referrals to pediatric rheumatologists as these antibodies may be key indicators for specific pediatric rheumatologic diagnoses. The reliability and reproducibility of ANA tests varies with assay techniques and validation and interpretation of results. In the following article, review of ANA testing in pediatrics is provided along with case examples that demonstrate the reliability and reproducibility of these results in specific scenarios common in the practice of pediatric rheumatology. Guidelines for more accurate utilization of ANA testing are presented with the aim to improve testing and interpretation by ordering clinicians.
Collapse
|
5
|
Ben Jdidia I, Zribi K, Boubaker M, Brahem A, Sayadi M, Tlijani M, Saidani Z, Cherif A. Les médicaments qui interfèrent avec les bilans biologiques : revue de la littérature. Can J Hosp Pharm 2021; 74:378-385. [PMID: 34602626 PMCID: PMC8463014 DOI: 10.4212/c-jhp.v74i4.3200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
BACKGROUND Biological assessment is an integral part of the diagnostic process that guides therapeutic management decisions. However, these analyses remain subject to interference from endogenous or exogenous factors, which may alter the results. OBJECTIVE To provide an up-to-date and comprehensive overview of the most commonly documented types of interference attributable to medications, to ensure reliable interpretation of test results and better management of patients. DATA SOURCES This comprehensive systematic review of the literature was carried out in 2018. The bibliographic search was carried out in various online databases, specifically PubMed, ScienceDirect and Google Scholar. STUDY SELECTION Only publications in French or English concerning medicinal products for human use were retained. The investigators' examination of drug-related interference with laboratory tests was limited to blood assays (serum or plasma). DATA EXTRACTION An Excel spreadsheet was used to analyze the results. A total of 82 articles were selected. The interferences studied affected 47 biological parameters corresponding to various types of assessment: hormonal, hepatic, and renal. DATA SYNTHESIS The mechanisms reported in the literature identified were analytical (56.9%), physiological (17.82%), and pharmacological (20.11%). The remainder of the mechanisms (5.17%) were not defined. CONCLUSIONS Clinicians should be vigilant in validating and interpreting laboratory test results for patients receiving these types of drugs. Dialogue between clinicians and biological scientists is the best way to avoid unnecessary additional testing, which is often cumbersome and costly.
Collapse
Affiliation(s)
- Imene Ben Jdidia
- , Pharm. D., est une Pharmacienne spécialiste des hôpitaux et assistante hospitalo-universitaire en pharmacie hospitalière, Hôpital Fattouma Bourguiba de Monastir, Monastir, Tunisie
| | - Kaouther Zribi
- , Pharm. D., Ph. D., est une Pharmacienne spécialiste des hôpitaux et assistante hospitalo-universitaire en pharmacie hospitalière, Centre de maternité et de néonatologie de Monastir, Monastir, Tunisie
| | - Meriam Boubaker
- , Pharm. D., est une Pharmacienne et responsable de recherche et développement, Génome Humain et Maladies Multifactorielles (LR12ES07), Faculté de pharmacie, Université de Monastir, Monastir, Tunisie
| | - Amira Brahem
- , Pharm. D., est Pharmacienne et responsable de recherche et développement, Génome Humain et Maladies Multifactorielles (LR12ES07), Faculté de pharmacie, Université de Monastir, Monastir, Tunisie
| | - Mouna Sayadi
- , Pharm. D., est une Pharmacienne spécialiste des hôpitaux et assistante hospitalo-universitaire en pharmacie hospitalière, Centre de maternité et de néonatologie de Monastir, Monastir, Tunisie
| | - Marwa Tlijani
- , Pharm. D., est une Pharmacienne spécialiste des hôpitaux et assistante hospitalo-universitaire en pharmacie hospitalière, Centre de maternité et de néonatologie de Monastir, Monastir, Tunisie
| | - Zahra Saidani
- , MD, Médecin spécialiste en gynécologie et obstétrique, est professeur en médecine, Centre de maternité et de néonatologie de Monastir, Monastir, Tunisie
| | - Amani Cherif
- , Pharm. D., Ph. D., est une Pharmacienne spécialiste des hôpitaux et professeur agrégé en pharmacie hospitalière, Centre de maternité et de néonatologie de Monastir, Génome Humain et Maladies Multifactorielles (LR12ES07), Faculté de pharmacie, Université de Monastir, Monastir, Tunisie
| |
Collapse
|
6
|
Gonel A, Kirhan I, Koyuncu I, Bayraktar N, Karadag ME, Karadag M. The Role of Interferences in the Increasing Incidence of Vitamin D Deficiency. Endocr Metab Immune Disord Drug Targets 2020; 20:1303-1308. [PMID: 32496995 DOI: 10.2174/1871530320666200604160208] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 12/08/2019] [Accepted: 04/10/2020] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Lipemia is one of the causes of interference in immunoassay and LC-MS/MS methods. Increased prevalence of vitamin D deficiency in the US, where obesity is gradually increasing, raises the suspicion that high levels of fat diet and blood lipid levels interfere with vitamin D measurement results. The focus of this study was to investigate the effect of blood lipid profiles on vitamin D results and prevent the matrix effect. MATERIAL AND METHODS In this study, 25OH vitamin D3 (25OHD3) levels of 100 samples consecutively accepted to biochemistry laboratory regardless of age and sex were measured by the LC-MS/MS method, and each sample was restudied after 1/10 dilution. After dilution restudy, two groups were obtained-group 1 (results deviating below 20%) and group 2 (results deviating above 20%)-and the difference between the groups was investigated. There were 79 patients in group 1 and 21 patients in group 2. In our study, lipid profiles (triglyceride, total cholesterol, HDL, LDL) from the same samples of consecutive vitamin D patients were studied. RESULTS It was observed that the triglyceride, total cholesterol HDL, LDL, and 25OHD3 measurements of group 1 and group 2 were similar (p > 0.05). While the mean vitamin D value in the second group was 9.94 ± 7.85, the mean vitamin D value after dilution was measured as 39.23 ± 18.13 and was statistically significant. 25OHD3 concentrations of 21 patients out of 100 were found to be falsely low. Measurements were repeated to confirm the results. CONCLUSION The matrix effect caused by exogenous and endogenous interferences in the blood could be a hidden factor increasing the prevalence of vitamin D deficiency by causing falsely low 25OHD3 values. Suspicious results should be remeasured by a dilution study.
Collapse
Affiliation(s)
- Ataman Gonel
- Department of Biochemistry, Harran University, Faculty of Medicine, Sanliurfa, Turkey
| | - Idris Kirhan
- Department of Internal Medicine, Harran University, Faculty of Medicine, Sanliurfa, Turkey
| | - Ismail Koyuncu
- Department of Biochemistry, Harran University, Faculty of Medicine, Sanliurfa, Turkey
| | - Nihayet Bayraktar
- Department of Biochemistry, Harran University, Faculty of Medicine, Sanliurfa, Turkey
| | - Mujgan Ercan Karadag
- Department of Biochemistry, Harran University, Faculty of Medicine, Sanliurfa, Turkey
| | - Mehmet Karadag
- Department of Biostatistics and Bioinformatics, Mustafa Kemal University, Faculty of Medicine, Hatay, Turkey
| |
Collapse
|
7
|
Ong L, Abid MB, Yip A, Choong C, Chng WJ, de Mel S. Paraprotein interference in the diagnosis of hepatitis C infection. Clin Chem Lab Med 2018; 56:e194-e196. [DOI: 10.1515/cclm-2017-1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Accepted: 01/28/2018] [Indexed: 11/15/2022]
|
8
|
Zhang Z, Hu W, Li L, Ding H, Li H. Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected? J Clin Lab Anal 2017; 32. [PMID: 28810082 DOI: 10.1002/jcla.22307] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Accepted: 07/22/2017] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND We herein provide an overview of the clinical laboratory tests that should be performed before, during and after using therapeutic monoclonal antibodies (mAbs) and the clinical laboratory tests that may be affected by mAbs. METHODS The labels of FDA-approved therapeutic mAbs were downloaded from DailyMed (the official website for drug labels) and were used as the sources of data for this review. RESULTS It was found that most of the labels provided information relevant to the clinical laboratory tests, including the tests needed before mAbs treatment to check the patients' background status and to identify potentially sensitive patients, the tests needed during or after the treatment to evaluate the patients' response, and the mAbs that may lead to false positive or negative results for clinical laboratory tests. CONCLUSIONS The present findings will be of interest to physicians, laboratory scientists, those involved in drug development and surveillance and individuals making health care policy.
Collapse
Affiliation(s)
- Zhanhu Zhang
- Institute of Medical Genetics and Reproductive Medicine, Nantong Maternity and Child Health Hospital, Nantong, Jiangsu, China
| | - Wenjie Hu
- Department of Clinical Laboratory Medicine, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, China
| | - Linlin Li
- Department of Clinical Laboratory Medicine, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, China
| | | | - Haibo Li
- Department of Clinical Laboratory Medicine, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, China
| |
Collapse
|
9
|
Moreau P, van de Donk NWCJ, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2017; 76:853-67. [PMID: 27113582 DOI: 10.1007/s40265-016-0573-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number of mAbs directed at myeloma cell surface molecules are in development. Daratumumab is a CD38 mAb that has demonstrated substantial activity and good tolerability in four phase I, phase I/II and phase II studies as monotherapy, as well as in combination with current standard treatments in MM. The positive results obtained in the relapsed/refractory setting in patients with advanced-stage disease and in a small number of patients with newly diagnosed disease provide the rationale for the investigation of the agent in a number of ongoing phase III trials. mAbs are generally better tolerated than conventional chemotherapy; however, their use requires other special considerations. Such factors include those common to all mAbs, namely infusion-related reactions, but also factors that are observed with mAbs used in myeloma, such as interference with response assessment, or factors that are related to CD38 mAbs such as daratumumab, for instance blood typing interference. Our review provides an overview of the results from the daratumumab clinical trials conducted to date, as well as practical management considerations for the use of daratumumab based on our experience with the agent.
Collapse
Affiliation(s)
- Philippe Moreau
- Hematology Department, University Hospital Hôtel-Dieu, Place Ricordeau, 44093, Nantes, France.
| | | | | | - Henk Lokhorst
- VU University Medical Center, Amsterdam, The Netherlands
| | - Hareth Nahi
- Karolinska University Hospital Huddinge, Stockholm, Sweden
| | | | | | | | | | | | - Sonja Zweegman
- VU University Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | - Torben Plesner
- Vejle Hospital and University of Southern Denmark, Vejle, Denmark
| | | | | | | | | |
Collapse
|
10
|
Abstract
In recent decades, innovative strategies to treat patients with inflammatory, immunologically based diseases have advanced in concert with our increased understanding of molecular immunology. Recognition of the spectrum and pathophysiology of autoimmune and autoinflammatory disorders has allowed for the development of cutting-edge therapies for such patients. In this review, key immunotherapeutic approaches for treating inflammatory autoimmune disorders, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), as well as genetic autoinflammatory diseases, such as cryopyrin associated periodic syndromes, are addressed. Indications, risks and additional considerations in the use of these agents are reviewed.
Collapse
Affiliation(s)
- Barbara E Ostrov
- a Department of Pediatrics , Pediatric Rheumatology and Rheumatology, Pediatrician-in-Chief of Penn State Hershey Children's Hospital , Hershey , PA , USA
| |
Collapse
|
11
|
Yao H, Rayburn ER, Shi Q, Gao L, Hu W, Li H. FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels. Crit Rev Clin Lab Sci 2016; 54:1-17. [PMID: 27193822 DOI: 10.1080/10408363.2016.1191425] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Drug-related laboratory test interference or drug/laboratory test interactions (DLTI) are a major source of laboratory errors. DLTI is of concern with regard to both the clinical diagnosis and the monitoring of patients. Although there have been numerous reports about specific drugs that interfere with laboratory tests, there has not been a recent review on the topic. We herein provide a review of the known DLTI of US FDA-approved drugs based on a systematic search of DailyMed, a website containing the labels of US FDA-approved drugs. The labels for all human single-ingredient prescription drugs included in the database (1368) were searched using stemmed keywords and were manually reviewed for their relevance to DLTI. A total of 134 labels were positive, which indicated that the drug interferes with at least one clinical laboratory test. Antibacterial agents, psychotropic drugs and contrast media are the classes of drugs most likely to lead to DLTI. Urine was the clinical sample most frequently affected by DLTI. The FDA drug label is a source of information for studies of DLTI, although information is still lacking for most drugs, and additional improvements are needed for many of the existing records. Medical professionals, clinicians and laboratory staff should keep these possible interactions in mind when interpreting the results of laboratory tests, and should ensure that they obtain a complete and accurate record of all drugs being used by patients in order to anticipate potential DLTI. The development of a reporting system to address potential DLTI is warranted.
Collapse
Affiliation(s)
- Hui Yao
- a Department of Clinical Laboratory Medicine , Nantong Maternity and Child Health Hospital , Nantong , P.R. China
| | - Elizabeth R Rayburn
- b CLIA Laboratory Director (various laboratories) , Birmingham , AL , USA , and
| | - Qiang Shi
- c Division of Systems Biology , National Center for Toxicological Research, U.S. Food and Drug Administration , Jefferson , AR , USA
| | - Liang Gao
- a Department of Clinical Laboratory Medicine , Nantong Maternity and Child Health Hospital , Nantong , P.R. China
| | - Wenjie Hu
- a Department of Clinical Laboratory Medicine , Nantong Maternity and Child Health Hospital , Nantong , P.R. China
| | - Haibo Li
- a Department of Clinical Laboratory Medicine , Nantong Maternity and Child Health Hospital , Nantong , P.R. China
| |
Collapse
|
12
|
Rittenhouse-Olson K. Letter from the editor: immunological Investigations. Immunol Invest 2014; 43:727-33. [PMID: 25296230 DOI: 10.3109/08820139.2014.962855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|